Novo Nordisk (NVO) announced that the Food and Drug Administration has approved Ozempic to reduce the risk of kidney disease worsening, kidney ...

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular ...

Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing kidney failure risk, disease progression, and death due to ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this ...

A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.

Commonly used diabetes drugs could lower the risk of cardiometabolic conditions but heighten the risk of gastrointestinal and ...

BMO Capital Markets affirmed their positive stance on Novo Nordisk (NYSE:NVO) shares, maintaining an Outperform rating and a $105.00 price target. This confirmation followed the U.S. Food and Drug ...

The FDA's approval is based on the results of the FLOW phase 3b kidney outcomes trial. The trial revealed that Ozempic® 1 mg significantly lowered the relative risk of worsening kidney disease, kidney ...

The effects of SGLT2 inhibitors on the kidney to prevent progression of chronic kidney disease, congestive heart failure, ...